News from takeda pharmaceutical company limited A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Aug 21, 2013, 05:00 ET Data Published in the New England Journal of Medicine for Vedolizumab, an Investigational New Drug from Takeda for Moderately to Severely Active Ulcerative Colitis and Crohn's Disease

Takeda Pharmaceutical Company Limited ("Takeda") today announced that results from two Phase 3 studies evaluating vedolizumab, an investigational...


Jul 17, 2013, 11:45 ET Takeda and Zinfandel Pharmaceuticals Announce Results of a Study of the Performance Characteristics of a Genetics-Based Biomarker Risk Assignment Algorithm to Identify Risk of Mild Cognitive Impairment Due to Alzheimer's Disease

Takeda Pharmaceutical Company Limited ("Takeda") and its wholly-owned subsidiary, Takeda Development Center Americas, Inc. and its partner, Zinfandel ...


Jun 21, 2013, 08:00 ET Takeda Submits Biologics License Application for a New Investigational Drug Vedolizumab, in Moderately to Severely Active Crohn's Disease and Ulcerative Colitis in the United States

Takeda Pharmaceutical Company Limited ("Takeda") and its wholly-owned subsidiary, Takeda Pharmaceuticals U.S.A., Inc., today announced that a...


Jun 17, 2013, 10:00 ET Takeda Type 2 Diabetes Therapies, NESINA (alogliptin) and Fixed-Dose Combinations KAZANO (alogliptin and metformin HCl) and OSENI (alogliptin and pioglitazone), Are Now Available in Pharmacies in the United States

Takeda Pharmaceutical Company Limited (Takeda) and its wholly-owned subsidiary, Takeda Pharmaceuticals U.S.A., Inc. today announced that NESINA...


May 09, 2013, 02:08 ET Takeda Pharmaceutical Company Limited Announces Financial Results for the Fiscal Year Ended March 31, 2013 and Forecasts for the Fiscal Year Ending March 31, 2014

Takeda Pharmaceutical Company Limited ("Takeda", "the Company") announced today the consolidated financial results for the fiscal year ended March...


May 07, 2013, 07:00 ET Takeda to Acquire Inviragen, Inc.

Takeda Pharmaceutical Company Limited ("Takeda") and Inviragen, Inc. ("Inviragen") jointly announced today that Takeda, its wholly owned subsidiary...


Mar 12, 2013, 09:00 ET Takeda soumet une demande d'autorisation de mise sur le marché auprès de l'EMA pour le vedolizumab, traitement dans la maladie de Crohn et la rectocolite hémorragique modérées à sévères

Takeda Pharmaceutical Company Limited (« Takeda ») a annoncé aujourd'hui qu'une demande d'autorisation de mise sur le marché (AMM) a été déposée...


Mar 11, 2013, 09:00 ET Takeda presenta en la UE la solicitud de autorización de comercialización para vedolizumab en colitis ulcerosa y enfermedad de Crohn activas

-Takeda presenta en la Unión Europea la solicitud de autorización de comercialización para vedolizumab en colitis ulcerosa y enfermedad de Crohn...


Mar 08, 2013, 11:00 ET Takeda beantragt Genehmigung für das Inverkehrbringen von Vedolizumab gegen mäßig bis stark aktive Colitis ulcerosa und Morbus Crohn in der Europäischen Union

Takeda Pharmaceutical Company Limited ("Takeda") gab heute bekannt, dass das Unternehmen bei der Europäischen Arzneimittel-Agentur (EMA) einen...


Mar 08, 2013, 11:00 ET Takeda presenta la richiesta di autorizzazione all'immissione in commercio nell'Unione Europea per Vedolizumab nella colite ulcerosa moderata-grave e nella malattia di Crohn

Takeda Pharmaceutical Company Limited ("Takeda") ha annunciato oggi di aver presentato una richiesta di Autorizzazione all'Immissione in Commercio...


Mar 07, 2013, 10:18 ET Takeda Submits Marketing Authorisation Application for Vedolizumab in Moderately to Severely Active Ulcerative Colitis and Crohn's Disease in the European Union

Takeda Pharmaceutical Company Limited ("Takeda") today announced that a Marketing Authorisation Application (MAA) has been submitted to The European...


Jan 25, 2013, 06:55 ET Takeda Receives FDA Approval for Three New Type 2 Diabetes Therapies, NESINA (alogliptin) and Fixed-Dose Combinations OSENI (alogliptin and pioglitazone) and KAZANO (alogliptin and metformin HCl)

Takeda Pharmaceutical Company Limited (Takeda) and its wholly-owned subsidiary, Takeda Pharmaceuticals U.S.A., Inc. today announced that the United...


Dec 24, 2012, 06:00 ET Takeda Announces Mutual Termination of Amylin / Takeda Worldwide Agreement to Co-Develop and Commercialize Compounds for Obesity

Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that it has mutually terminated its worldwide agreement with Amylin...


Dec 17, 2012, 09:00 ET Takeda to Sell Non-Colcrys URL Pharma, Inc. Generic Business to Sun Pharmaceutical

Takeda Pharmaceutical Company Limited (Takeda) announced today that Takeda's wholly-owned subsidiary, Takeda Pharmaceuticals U.S.A., Inc. (TPUSA) has ...


Jul 27, 2012, 02:30 ET Takeda Resubmits New Drug Applications to the United States Food and Drug Administration for Alogliptin and the Fixed-Dose Combination Alogliptin and Pioglitazone

Takeda Pharmaceutical Company Limited (Takeda) announced today that its wholly-owned subsidiary, Takeda Global Research & Development Center, Inc.,...


Jun 20, 2012, 11:11 ET Takeda Anuncia la Aceptación a Trámite por parte de la EMA de Dos Terapias para Diabetes Tipo 2

- Takeda anuncia la aceptación a tramite por parte de la Agencia Europea de Medicamentos de las solicitudes de dos terapias de combinación de dosis...


Jun 04, 2012, 08:00 ET Takeda Completes Acquisition of URL Pharma, Inc.

Takeda Pharmaceutical Company Limited (Takeda) and its wholly owned subsidiary, Takeda Pharmaceuticals U.S.A., Inc. (TPUSA), jointly announced that...


May 25, 2012, 04:19 ET Takeda to Acquire Multilab, Enhancing its Business Infrastructure in Brazil

 Takeda Pharmaceutical Company Limited (Osaka, Japan, "Takeda") and Multilab Indústria e Comércio de Produtos Farmacêuticos Ltda. (Rio Grande do...


Apr 25, 2012, 09:45 ET Takeda Receives Complete Response Letter from the FDA for Type 2 Diabetes Investigational Therapies Alogliptin and Fixed-Dose Combination Alogliptin and Pioglitazone

Takeda Pharmaceutical Company Limited (Takeda) and its wholly-owned subsidiary, Takeda Global Research & Development Center, Inc. today announced...


Apr 11, 2012, 05:21 ET Takeda to Acquire URL Pharma

Takeda Pharmaceutical Company Limited (Takeda) and URL Pharma Inc. (URL Pharma) jointly announced today that Takeda's wholly-owned subsidiary, Takeda ...


Feb 26, 2012, 06:36 ET Phase 2 Data of Takeda's Investigational GPR40 Agonist, Published in The Lancet, Demonstrated Improved Glycemic Control in Patients with Type 2 Diabetes

Phase 2 clinical data of an investigational type 2 diabetes therapy, TAK-875 of Takeda Pharmaceutical Company Limited ("Takeda"), were published...


Feb 06, 2012, 07:00 ET EDARBYCLOR (azilsartan medoxomil and chlorthalidone) Now Available in U.S. Pharmacies for Patients with Hypertension

Takeda Pharmaceutical Company Limited (Takeda) and its wholly-owned subsidiary, Takeda Pharmaceuticals U.S.A., Inc., today announced EDARBYCLOR...


Jan 18, 2012, 04:00 ET Takeda Announces Strategic Measures to Achieve Efficiencies for Long-Term Growth

Takeda Pharmaceutical Company Limited ("Takeda", TSE: 4502) announced today strategic measures to better align its global workforce and consolidate...


Jan 10, 2012, 02:00 ET Europäische Kommission schließt sich der Überzeugung der Europäischen Arzneimittelagentur an, dass Pioglitazon enthaltende Arzneimittel auch weiterhin eine zulässige Behandlungsoption für bestimmte Typ-2-Diabetespatienten bleibt

Die Neubewertung der Europäischen Kommission ist mit der Akzeptierung des CHMP-Standpunktes vom Oktober 2011 nun abgeschlossen Takeda Pharmaceutical...


Jan 10, 2012, 02:00 ET La Agencia Europea del Medicamento confirma que la pioglitazona es válida para tratar la diabetes de tipo 2

- La Comisión Europea adopta la opinión de la Agencia Europea del Medicamento que confirma que los medicamentos que contienen pioglitazona siguen...